Trial Profile
A Three Part, Non-randomized, Open Label Study Designed to Assess the Pharmacokinetics of GSK2982772 Following Administration of Minitab Modified Release Formulations in a Capsule Relative to an Immediate Release Reference Tablet Formulation (Part A), the Pharmacokinetics of Escalating, Repeat Doses of a Selected Minitab Modified Release Prototype (Part B) , and the Pharmacokinetics of GSK2982772 Following Administration of Modified Release Tablet Formulations in the Fed and Fasted State (Part C) in Healthy Participants
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Aug 2023
Price :
$35
*
At a glance
- Drugs GSK 2982772 (Primary) ; GSK 2982772 (Primary)
- Indications Inflammatory bowel diseases; Plaque psoriasis; Rheumatoid arthritis; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 01 Jul 2021 Part A of the study showed that the MT capsule formulations were susceptible to a food effect. Hence, a protocol was amended to add Part C to the study to investigate a larger matrix monolithic (MM) tablet formulation, according to results published in the Pharmaceutical Research.
- 08 Jan 2019 Status changed from recruiting to completed.
- 11 Oct 2018 Planned End Date changed from 31 Oct 2018 to 13 Nov 2018.